SCHEMBL3430383

SCHEMBL3430383

C#Cc1c(O)ccc(OC)c1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 5/20 0.42
▸ PDE4A P27815 4/20 0.42
▸ PDE4C Q08493 4/20 0.42
▸ PDE4D Q08499 4/20 0.42
▸ HIF1A Q16665 1/20 0.41
▸ EPAS1 Q99814 1/20 0.41
▸ FABP3 P05413 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ FABP5 Q01469 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ TDO2 P48775 1/20 0.40
▸ TUBB1 Q9H4B7 1/20 0.37
▸ MAPT P10636 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28367940 0.82 FABP4 (0.38) PDE4BPDE4APDE4CPDE4DFABP3
SCHEMBL30372439 0.81 CYP19A1 (0.39) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL28367468 0.81 FABP4 (0.40) PDE4BPDE4APDE4CPDE4DFABP3
SCHEMBL8329781 0.79 PDE4B (0.50) PDE4BPDE4APDE4CPDE4DHIF1A
SCHEMBL3432260 0.78 IMPDH2 (0.49) MAPTLMNAHTTSMN1; SMN2KDM4E
SCHEMBL7423032 0.78 PDE4B (0.58) PDE4BPDE4APDE4CPDE4DHIF1A
SCHEMBL27461313 0.75 PDE4B (0.46) PDE4BPDE4APDE4CPDE4DHIF1A
SCHEMBL5433427 0.72 CA1 (0.59) PDE4BPDE4APDE4CPDE4DFABP3
SCHEMBL20565891 0.72 MAPT (0.57) CA1CA2TP53TSHRMAPT
SCHEMBL11307508 0.71 EP300 (0.46) PDE4BPDE4APDE4CPDE4DHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273772-A1 Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) WYETH LLC (US) 2010-10-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273772-A1 Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) GRM5, GRM1, GRM2 PDE4B 1354/4885PDE4A 1072/4885PDE4C 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback